查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012144

糖尿病治疗市场：2026-2032年全球市场预测（按药物类别、患者类型、给药途径、治疗方法、分销管道和最终用户划分）

Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Therapy Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，糖尿病药物市场价值将达到 1,017.2 亿美元，到 2026 年将成长至 1,117.1 亿美元，到 2032 年将达到 2,174.9 亿美元，复合年增长率为 11.46%。

主要市场统计数据
基准年 2025 1017.2亿美元
预计年份：2026年 1117.1亿美元
预测年份 2032 2174.9亿美元
复合年增长率 (%) 11.46%

对不断发展的抗糖尿病药物趋势进行简要概述，重点关注临床进展、患者需求和商业性发展。

糖尿病治疗领域正处于持续演变之中，其驱动力来自临床创新、不断变化的患者期​​望以及医疗政策重点的调整。本文概述了抗糖尿病治疗的关键临床类别、新型生物製药与先进口服药物的交叉领域，以及相关人员在研发、采购和交付各阶段所面临的营运挑战。透过将目前进展置于更广泛的医疗服务体系中，本文重点阐述了治疗方法选择如何日益受到作用机制、病患合併症和长期疗效目标差异的影响。

精准医疗、数位疗法和基于价值的支付模式正在推动糖尿病照护发生变革性转变，惠及所有相关人员。

科学突破和系统性创新正在共同推动糖尿病治疗的变革，并改变临床路径和商业模式。精准医疗和肠促胰素生物製药拓展了治疗选择，而胰岛素类似物和给药装置的迭代改进显着提升了安全性和患者便利性。同时，数位化疗法、远距监测和整合式医疗平台的日益成熟，使得更持续的管理模式成为可能，这些技术也正逐步融入标准诊疗流程。

对 2025 年美国关税政策调整对供应链、定价和准入途径的连锁反应进行全面分析。

贸易和关税框架的政策调整可能会在全球医药供应链中引发新的摩擦，其中已宣布的2025年调整将对营运和策略产生直接影响。对于依赖跨国采购生产活性药物成分、初级包装或成品的企业而言，关税变化可能会改变成本结构，引发采购优先事项的重新分配，并对生产扩张计画造成压力。因此，供应链经理和采购负责人正日益重视供应商多元化、离岸外包和库存策略，以减轻关税对价格波动的影响。

关键细分洞察，用于解读药物类别、患者人口统计特征、给药途径、治疗模式、通路和最终用户需求。

建构精细的市场细分框架对于解读整个抗糖尿病药物市场的治疗趋势和竞争格局至关重要。本研究依药物类别分析市场，重点在于胰岛素和口服药物。胰岛素进一步细分为胰岛素类似物和人类胰岛素，其中胰岛素类似物细分市场将根据其不同的临床应用和装置相容性，进一步细分为长效、速效和超长效製剂。同时，口服药物类别进一步细分为双胍类、DPP-4抑制剂、GLP-1受体促效剂、SGLT-2抑制剂和磺酰尿素类，每种药物均需考虑其不同的作用机制和安全性与有效性之间的权衡。

美洲、欧洲、中东和非洲以及亚太地区的区域性和细微市场趋势，重点在于进入和创新的驱动因素。

区域差异对全球治疗方法的采纳、监管时间表和报销框架都产生了显着影响。在美洲，医疗保健系统涵盖了公私合作模式和主要由私人保险公司运营的模式，这种多样性影响着处方药的上市谈判、市场准入管道以及创新产品的推广速度。在该地区运营的製造商通常优先考虑产生真实世界数据 (RWE)，并与保险公司合作，以证明其产品在不同的报销条件下具有价值。

策略性企业趋势揭示领先製药和生技公司的研发重点、合作模式和竞争定位

糖尿病治疗领域的主要企业正透过整合强大的临床研发管线、策略合作伙伴关係以及对以患者为中心的技术的投资来脱颖而出。研发重点日益集中在那些除了血糖控制之外还能带来其他益处（例如心血管和肾臟保护）的药物，而研发策略则侧重于改进药物配方，以提高患者的用药依从性并减轻治疗负担。製药开发商与数位医疗公司之间的合作正在加速将远端监测、用药依从性支援和数据分析整合到治疗方案中，从而形成能够更好地应对慢性疾病管理的综合解决方案。

为行业领导者提供切实可行的建议，以加快部署、增强供应链韧性并优化以患者为中心的护理路径。

产业领导者应采取一系列切实可行的措施，以增强竞争韧性并加速患者群体治疗效果的提升。首先，应整合实证策略和商业计划，并设计临床开发项目以支持与保险公司的对话和长期疗效评估。透过将临床终点与实际应用结合，企业可以缩短报销时间并提升处方集的排名。其次，应实现供应链多元化，并投资制定短期紧急时应对计画，以降低关税变化、地缘政治格局变化和生产中断等风险。

一套稳健的调查方法，描述了为确保资料来源、分析框架、检验过程和方法的严谨性而采取的措施。

本分析的调查方法透过整合多源证据、专家检验和迭代分析审查，确保了研究的严谨性和有效性。主要资讯来源包括同行评审的临床文献、监管指导文件和公开的临床试验註册数据，这些数据被整合起来，以揭示治疗机制、安全性特征和不断变化的终点指标。此外，产业资讯披露和公司备案文件也被作为补充​​，用于了解策略倡议和技术投资。

结合临床趋势、政策影响、细分市场洞察以及对相关人员。

这项综合分析结合了临床创新、政策趋势、市场区隔和区域差异，描绘出一幅现代抗糖尿病疗法的完整整体情况。新兴生物製药和新一代胰岛素製剂正在重塑治疗模式，而数位医疗和基于价值的报销模式的融合正在改变实证医学的产生方式和治疗方法的采购方式。同时，关税和贸易政策的变化如同营运压力测试，暴露了供应链的脆弱性，并迫使采购和分销环节进行策略调整。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 糖尿病治疗市场：依药物类别划分

  • 胰岛素
    • 胰岛素类似物
      • 长效型
      • 快速起效
      • 超长效
    • 人类胰岛素
  • 口服药物
    • 双胍类药物
    • DPP-4抑制剂
    • GLP-1受体促效剂
    • SGLT-2抑制剂
    • 磺酰尿素类药物

第九章：依患者类型分類的糖尿病药物市场

  • 妊娠糖尿病
  • 糖尿病前期
  • 1型糖尿病
  • 2型糖尿病

第十章：糖尿病治疗市场：依给药途径划分

  • 口服
  • 肠外

第十一章 糖尿病药物市场依治疗方法

  • 联合治疗
  • 单药治疗

第十二章 糖尿病药物市场：依分销管道划分

  • 离线
  • 在线的

第十三章 糖尿病治疗市场：依最终使用者划分

  • 诊所
  • 居家照护
  • 医院

第十四章 糖尿病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 糖尿病药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 糖尿病药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国糖尿病治疗市场

第十八章：中国糖尿病治疗药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
Product Code: MRR-437896AA366F

The Antidiabetic Drugs Market was valued at USD 101.72 billion in 2025 and is projected to grow to USD 111.71 billion in 2026, with a CAGR of 11.46%, reaching USD 217.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 101.72 billion
Estimated Year [2026] USD 111.71 billion
Forecast Year [2032] USD 217.49 billion
CAGR (%) 11.46%

A concise introduction to the evolving antidiabetic therapeutics landscape highlighting clinical advances, patient needs, and commercial dynamics

The therapeutic landscape for diabetes is undergoing a period of sustained evolution driven by clinical innovation, changing patient expectations, and shifting health policy priorities. This introduction frames the critical clinical categories of antidiabetic therapy, the intersection of novel biologics and advanced oral agents, and the operational pressures that stakeholders face across development, procurement, and care delivery. By situating current advances within a broader continuum of care, the narrative highlights how therapeutic choices are increasingly informed by mechanistic differentiation, patient comorbidities, and long-term outcome objectives.

Moreover, contemporary decision-making is shaped by digital health adoption, real-world evidence generation, and tighter regulatory scrutiny of safety and value. As a result, manufacturers, payers, and providers are required to balance speed of innovation with demonstrable improvements in adherence, glycemic control, and complication prevention. The following analysis is intended to orient readers to these converging forces and to provide a concise foundation for the deeper thematic sections that follow, enabling informed interpretation of subsequent insights on segmentation, regional dynamics, policy impacts, and strategic responses.

Transformational shifts reshaping diabetes care driven by precision medicines, digital therapeutics, and value-based payment models across stakeholders

Diabetes care is being transformed by a combination of scientific breakthroughs and system-level innovations that together alter clinical pathways and commercial models. Precision medicines and incretin-based biologics have expanded the therapeutic toolkit, while iterative improvements in insulin analog formulations and delivery devices have materially enhanced safety profiles and patient convenience. Simultaneously, the maturation of digital therapeutics, remote monitoring, and integrated care platforms is enabling more continuous management approaches, and these modalities are progressively woven into standard care algorithms.

In addition, payment and reimbursement models are shifting toward value-based contracting that ties reimbursement to outcomes rather than units dispensed. This change incentivizes manufacturers to demonstrate durable clinical benefits, improves alignment between providers and payers, and accelerates partnerships across the healthcare ecosystem. As a result, product development priorities now emphasize long-term cardiovascular and renal endpoints, adherence optimization, and patient-centered outcomes. Looking forward, convergence between pharmacology, device innovation, and data-driven care delivery will continue to redefine competitive advantage and the pathways through which patients access and remain on therapy.

Comprehensive analysis of how United States tariff policy adjustments in 2025 could reverberate through supply chains, pricing, and access pathways

Policy shifts in trade and tariff frameworks can introduce new frictions into global pharmaceutical supply chains, and the adjustments announced for 2025 have immediate operational and strategic implications. For organizations that rely on transnational sourcing of active pharmaceutical ingredients, primary packaging, or finished-dose manufacturing, tariff alterations can change cost structures, reallocate procurement priorities, and pressure timelines for scale-up. Consequently, supply-chain managers and procurement officers are increasingly evaluating supplier diversification, nearshoring, and inventory strategies to mitigate exposure to tariff-induced price volatility.

Moreover, changes in import duties can influence downstream pricing and payer negotiations, particularly in segments where competition is price-sensitive or where biosimilar entrants are accelerating therapeutic substitution. Reimbursement stakeholders may seek greater transparency on landed costs and supply risks as they negotiate formulary positioning and access pathways. From an operational perspective, manufacturers are also reassessing distribution agreements and contractual terms to preserve margin stability and maintain uninterrupted patient access. In sum, tariff policy adjustments function as a catalyst for more resilient sourcing strategies, tighter supplier collaboration, and increased emphasis on scenario planning to protect continuity of care.

Key segmentation insights decoding drug classes, patient populations, administration routes, therapy patterns, distribution paths and end-user demands

A nuanced segmentation framework is essential for interpreting therapeutic trends and competitive positioning across antidiabetic treatments. Based on Drug Class, the market is analyzed across Insulin and Oral Agents. Insulin is differentiated into Analog Insulin and Human Insulin, and the Analog Insulin segment is further examined across Long-Acting, Rapid-Acting, and Ultra-Long-Acting formulations to reflect their divergent clinical applications and device compatibilities. Meanwhile, the Oral Agents category is parsed into Biguanides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and Sulfonylureas, acknowledging distinct mechanisms of action and safety-efficacy trade-offs.

In addition to molecular class, segmentation by Patient Type separates clinical approaches for Gestational Diabetes, Prediabetes, Type 1 Diabetes, and Type 2 Diabetes, which clarifies differing therapeutic objectives and adherence patterns. The Route Of Administration axis distinguishes Oral and Parenteral delivery pathways, calling attention to formulation development and device strategy. Therapy Type compares Combination Therapy and Monotherapy to illuminate prescribing behavior and regimen complexity. Distribution Channel contrasts Offline and Online pathways, highlighting shifts in pharmacy access and digital dispensing models. Finally, End User classification across Clinics, Home Care, and Hospitals underscores where care delivery investments and patient education priorities should be concentrated.

Regional dynamics and nuanced market behavior across Americas, Europe Middle East & Africa, and Asia-Pacific emphasizing access and innovation drivers

Regional heterogeneity strongly influences therapeutic adoption, regulatory timelines, and reimbursement frameworks across the globe. In the Americas, health systems vary from integrated public-private models to predominantly private payer systems, and this variation affects formulary negotiation dynamics, routes to market, and the speed of innovative product uptake. Manufacturers operating in this region often prioritize real-world evidence generation and payer engagement to demonstrate value under diverse reimbursement conditions.

Across Europe, Middle East & Africa, regulatory harmonization and divergent purchasing mechanisms create both opportunities and complexities. In several European markets, centralized procurement and rigorous health-technology assessment processes necessitate robust clinical and economic evidence, while emerging markets in the Middle East and Africa may face constraints related to cold-chain logistics and access affordability. In contrast, the Asia-Pacific region comprises a mixture of highly developed regulatory ecosystems and rapidly expanding markets where demographic shifts and rising prevalence drive demand for scalable, accessible therapies. Consequently, strategies that account for regional infrastructure, local manufacturing potential, and tailored pricing approaches are essential for sustainable penetration and long-term patient access.

Strategic company landscapes revealing R&D priorities, collaboration models, and competitive positioning among leading pharmaceutical and biotech players

Leading companies in the antidiabetic domain are differentiating through a blend of deep clinical pipelines, strategic collaborations, and investments in patient-centric technologies. R&D priorities increasingly favor agents that demonstrate benefits beyond glycemic control, such as cardiovascular and renal protection, while development strategies also emphasize formulation enhancements that improve adherence and reduce treatment burden. Partnerships between pharmaceutical developers and digital health firms are accelerating the integration of remote monitoring, adherence interventions, and data analytics into therapeutic offerings, thereby creating bundled solutions that better address chronic disease management.

Competitive positioning is further shaped by geographic manufacturing footprints, supply-chain resilience, and capability in biologics development. Companies that combine robust clinical evidence generation with agile commercial models and payer engagement capabilities are best positioned to navigate complex reimbursement landscapes. In addition, smaller biotech firms and contract developers are contributing innovation in novel modalities and delivery technologies, often becoming acquisition targets or collaborators for larger organizations seeking to expand their therapeutic portfolios. Collectively, these strategic behaviors indicate a market environment where therapeutic differentiation, technical execution, and collaborative business models determine sustained leadership.

Actionable recommendations for industry leaders to accelerate adoption, strengthen supply resilience, and optimize patient-centric care pathways

Industry leaders should adopt a set of pragmatic actions to strengthen competitive resilience and to accelerate therapeutic impact across patient populations. First, integrate evidence-generation strategies with commercial planning so that clinical development programs are designed to support payer conversations and long-term outcomes assessment. By aligning clinical endpoints with real-world applicability, organizations can reduce time to reimbursement and improve formulary positioning. Second, diversify supply networks and invest in near-term contingency planning to mitigate risks associated with tariff changes, geopolitical shifts, and manufacturing disruptions.

Furthermore, prioritize patient-centered product design by investing in adherence-enhancing formulations and in digital tools that simplify disease management. Strengthening collaborations with providers and payers will facilitate outcome-based contracting and shared-risk agreements that align incentives across the care continuum. Finally, tailor regional go-to-market models to local infrastructure realities and regulatory expectations, and pursue strategic alliances with regional manufacturers or distributors to expedite access while optimizing cost structures. Together, these steps create a coherent roadmap for translating scientific innovation into measurable patient benefit and commercial sustainability.

Robust research methodology explaining data sources, analytical frameworks, validation processes, and steps taken to ensure methodological rigor

The research methodology underpinning this analysis combines multi-source evidence synthesis, expert validation, and iterative analytical review to ensure rigor and relevance. Primary inputs include peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries, which are synthesized to map therapeutic mechanisms, safety profiles, and evolving endpoint priorities. These sources are complemented by industry disclosures and company filings to understand strategic initiatives and technology investments.

Analytical frameworks incorporate qualitative expert interviews and scenario-based risk assessment to evaluate supply-chain vulnerabilities and policy impacts. Throughout the process, internal validation steps cross-reference clinical findings with regulatory trends and real-world evidence to ensure consistency. Sensitivity analyses and triangulation are applied to reconcile disparate inputs, and methodological transparency is maintained through detailed documentation of data sources, inclusion criteria, and analytical assumptions. This approach provides stakeholders with a defensible basis for strategic decision-making while remaining adaptable to new data as it emerges.

Conclusive synthesis that integrates clinical trends, policy impacts, segmentation insights, and forward-looking implications for stakeholders

This synthesis integrates clinical innovation, policy developments, segmentation clarity, and regional nuance to form a coherent picture of contemporary antidiabetic therapeutics. Emerging biologics and next-generation insulin formulations are reshaping treatment paradigms, while digital health integration and value-based reimbursement models are changing how evidence is generated and how treatments are procured. At the same time, tariff and trade policy shifts act as operational stress tests that expose supply-chain vulnerabilities and compel strategic adjustments in sourcing and distribution.

Collectively, these forces indicate that long-term success will favor organizations that combine scientific differentiation with operational agility and payer-centered evidence strategies. To navigate this landscape, stakeholders must prioritize patient-centric design, resilient procurement frameworks, and targeted regional approaches that account for regulatory and infrastructural variability. In doing so, they can better ensure sustained access to effective therapies and realize the clinical and economic benefits of contemporary diabetes care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antidiabetic Drugs Market, by Drug Class

  • 8.1. Insulin
    • 8.1.1. Analog Insulin
      • 8.1.1.1. Long-Acting
      • 8.1.1.2. Rapid-Acting
      • 8.1.1.3. Ultra-Long-Acting
    • 8.1.2. Human Insulin
  • 8.2. Oral Agents
    • 8.2.1. Biguanides
    • 8.2.2. DPP-4 Inhibitors
    • 8.2.3. GLP-1 Receptor Agonists
    • 8.2.4. SGLT-2 Inhibitors
    • 8.2.5. Sulfonylureas

9. Antidiabetic Drugs Market, by Patient Type

  • 9.1. Gestational Diabetes
  • 9.2. Prediabetes
  • 9.3. Type 1 Diabetes
  • 9.4. Type 2 Diabetes

10. Antidiabetic Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Antidiabetic Drugs Market, by Therapy Type

  • 11.1. Combination Therapy
  • 11.2. Monotherapy

12. Antidiabetic Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Antidiabetic Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Antidiabetic Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antidiabetic Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antidiabetic Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antidiabetic Drugs Market

18. China Antidiabetic Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Alkem Laboratories Ltd.
  • 19.7. Aristo Pharmaceuticals Pvt. Ltd.
  • 19.8. Astellas Pharma Inc.
  • 19.9. AstraZeneca PLC
  • 19.10. Biocon Limited
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Cadila Pharmaceuticals Limited
  • 19.13. Cipla Limited
  • 19.14. Dr. Reddy's Laboratories
  • 19.15. Eli Lilly and Company
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. GlaxoSmithKline PLC
  • 19.18. Glenmark Pharmaceuticals Ltd.
  • 19.19. Halozyme Therapeutics, Inc.
  • 19.20. Johnson & Johnson Services, Inc.
  • 19.21. Mankind Pharma Ltd.
  • 19.22. Merck KGaA
  • 19.23. Novo Nordisk A/S
  • 19.24. Oramed Pharmaceuticals Inc.
  • 19.25. Pfizer Inc.
  • 19.26. PHC Holdings Corporation
  • 19.27. Sanofi S.A.
  • 19.28. Takeda Pharmaceutical Company Limited
  • 19.29. Teva Pharmaceutical Industries Ltd.
  • 19.30. Tonghua Dongbao Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)